Metformin as antiviral therapy protects hyperglycemic and diabetic patients
mBio · 2025
DOI: 10.1128/mbio.00634-25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift mBio, 2025. Verfasst von Xi Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Antiviral Agents, Diabetes Mellitus, Hyperglycemia, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Foundation of State Key Laboratory of Pathogen and Biosecurity of China.
Abstract (Originalsprache)
Viral infections disrupt glucose metabolism; however, their impact on disease prognosis in highly pathogenic viruses remains largely unknown. There is an additional need to investigate the antiviral mechanisms of glucose-lowering therapeutics. Here, our multicenter clinical study shows that hyperglycemia and pre-existing diabetes are independent risk factors for mortality in patients infected with severe fever with thrombocytopenia syndrome virus (SFTSV), an emerging and highly pathogenic bunyavirus. SFTSV infection triggers gluconeogenesis, which, in turn, inhibits AMPK activity and subsequent interferon I (IFN-I) responses, thereby facilitating viral replication. In vitro and animal studies further reveal that metformin inhibits SFTSV replication by suppressing autophagy through the AMPK-mTOR pathway, contributing to protection against lethal SFTSV infection in mice. Importantly, our large cohort study demonstrates that metformin reduces viremia and SFTSV-related mortality in patients with hyperglycemia or pre-existing diabetes, contrasting with the disadvantageous effect of insulin. These findings highlight the promising therapeutic potential of metformin in treating viral infections, particularly among individuals with hyperglycemia or diabetes. IMPORTANCE Severe fever with thrombocytopenia syndrome virus (SFTSV), an emerging tick-borne bunyavirus, causes severe hemorrhagic fever with a high mortality rate. Previous studies have shown metabolic disturbances, particularly hyperglycemia, in SFTSV-infected individuals. However, the mechanism underlying this metabolic derangement remains unclear, and further investigation is needed to determine whether glucose-lowering therapeutics could be beneficial for SFTSV-infected patients. In this study, our multicenter clinical data show that hyperglycemia and pre-existing diabetes are independent risk factors for mortality in patients with SFTSV infection. Furthermore, we observed that SFTSV infection triggers gluconeogenesis, which promotes viral replication through the regulation of the AMPK-IFN-I signaling pathway. Notably, metformin significantly reduces viremia and SFTSV-related mortality in patients with hyperglycemia or pre-existing diabetes, attributed to its inhibitory effect on autophagy through the AMPK-mTOR pathway. Therefore, our study uncovers the interaction between SFTSV infection and glucose metabolic disorder and highlights the promising therapeutic potential of metformin for treating SFTSV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Anhui Medical University, Hefei, Anhui, China.
- State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
- School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- The 154th Hospital, China RongTong Medical Healthcare Group Co.Ltd, Xinyang, Henan, China.
- Yantai Qishan Hospital, Yantai, Shandong, China.
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Xiaojie Zheng, Hao Li, Wei Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Foundation of State Key Laboratory of Pathogen and Biosecurity of China
Zitieren
APA
Wang, X., Zheng, X., Ge, H., Cui, N., Lin, L., Yue, M., Zhu, C., Zhou, Q., Song, P., Shang, X., Wang, R., Wang, Z., Wang, Z., Zhang, Y., Yin, X., Yang, L., Su, H., Li, H., & Liu, W. (2025). Metformin as antiviral therapy protects hyperglycemic and diabetic patients. mBio. https://doi.org/10.1128/mbio.00634-25
Vancouver
Wang X, Zheng X, Ge H, Cui N, Lin L, Yue M, et al. Metformin as antiviral therapy protects hyperglycemic and diabetic patients. mBio. 2025. doi:10.1128/mbio.00634-25
BibTeX
@article{Wang2025,
author = {Wang, Xi and Zheng, Xiaojie and Ge, Honghan and Cui, Ning and Lin, Ling and Yue, Ming and Zhu, Chuanlong and Zhou, Qi and Song, Peixin and Shang, Xing and Wang, Rui and Wang, Zhen and Wang, Zhiyou and Zhang, Yunfa and Yin, Xiaohong and Yang, Linsheng and Su, Hong and Li, Hao and Liu, Wei},
title = {Metformin as antiviral therapy protects hyperglycemic and diabetic patients},
journal = {mBio},
year = {2025},
doi = {10.1128/mbio.00634-25}
}
EUVIMED